What are the side effects of Pramlintide (Symlin)?
The most commonly reported Pramlintide (Symlin) side effects are severe hypoglycemia (when paired with insulin without dose adjustment, boxed warning), nausea, vomiting, anorexia. Most are mild and tend to be dose dependent. It is generally avoided with hypoglycemia unawareness. Human clinical evidence for Pramlintide (Symlin) is limited, so this reflects reported and observed effects, not a complete safety profile.
Reported Pramlintide (Symlin) side effects
- Severe hypoglycemia (when paired with insulin without dose adjustment, boxed warning)
- Nausea, vomiting
- Anorexia
- Headache
Who should avoid it
- Hypoglycemia unawareness
- Gastroparesis
- A1C > 9%
- Pregnancy / nursing
Bloodwork worth tracking
- A1C
- Glucose monitoring
- Fasting insulin if on insulin therapy
References
- Pramlintide as an adjunct to insulin therapy in T1D, review — Edelman SV et al., Diabetes Technol Ther, 2008
- Addition of pramlintide to insulin therapy lowers HbA1c in conjunction with weight loss in patients with type 2 diabetes approaching glycaemic targets — Hollander P et al., Diabetes, Obesity & Metabolism, 2003
- Pramlintide in the management of insulin-using patients with type 2 and type 1 diabetes — Pullman J et al., Vascular Health and Risk Management, 2006
Pepdex is an editorial reference, not medical advice. Peptides vary in legal and approval status by country, many are research compounds without full human safety data. Talk to a qualified clinician before starting anything.
More on Pramlintide (Symlin)
Last updated 2026-06-06.